CS
BEAM icon

Credit Suisse’s Beam Therapeutics BEAM Stock Holding History

Credit Suisse’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.32M Sell
100,544
-10,289
-9% -$321K ﹤0.01% 1542
2023
Q4 		$3.02M Sell
110,833
-13,734
-11% -$341K ﹤0.01% 1642
2023
Q3 		$3M Buy
124,567
+28,522
+30% +$765K ﹤0.01% 1578
2023
Q2 		$3.07M Buy
96,045
+17,974
+23% +$583K ﹤0.01% 1657
2023
Q1 		$2.39M Buy
78,071
+3,805
+5% +$150K ﹤0.01% 1760
2022
Q4 		$2.9M Buy
74,266
+16,398
+28% +$734K ﹤0.01% 1659
2022
Q3 		$2.76M Buy
57,868
+3,725
+7% +$212K ﹤0.01% 1640
2022
Q2 		$2.1M Buy
54,143
+8,919
+20% +$355K ﹤0.01% 1877
2022
Q1 		$2.59M Sell
45,224
-9,149
-17% -$600K ﹤0.01% 1908
2021
Q4 		$4.33M Sell
54,373
-145,610
-73% -$12.5M ﹤0.01% 2133
2021
Q3 		$17.4M Buy
199,983
+171,014
+590% +$17.2M 0.01% 1159
2021
Q2 		$3.73M Buy
28,969
+5,168
+22% +$412K ﹤0.01% 2337
2021
Q1 		$1.91M Sell
23,801
-34,927
-59% -$3.32M ﹤0.01% 2859
2020
Q4 		$4.79M Buy
58,728
+49,907
+566% +$2.45M ﹤0.01% 2120
2020
Q3 		$218K Buy
+8,821
New +$219K ﹤0.01% 3806

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Credit Suisse's BEAM Position: Q1 2024 in Review

Credit Suisse reduced its Beam Therapeutics (BEAM) stake by 9.3% in Q1 2024, selling an estimated $321K and leaving 100,544 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1542.

Credit Suisse first reported a position in BEAM in Q3 2020 and has held it in 15 quarters since. The position peaked at $17.4M in Q3 2021. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Credit Suisse held 100,544 shares of Beam Therapeutics worth $3.32M as of Q1 2024.
  • Credit Suisse sold 10,289 Beam Therapeutics shares in Q1 2024, an estimated $321K.
  • Beam Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1542 holding.
  • Credit Suisse first reported a position in Beam Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Credit Suisse's Beam Therapeutics position peaked at $17.4M in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.